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Abstract
Increased -synuclein (syn) and mitochondrial dysfunction play central roles in the pathogenesis of Parkinson’s disease
(PD), and lowering syn is under intensive investigation as a therapeutic strategy for PD. Increased syn levels disrupt
mitochondria and impair respiration, while reduced syn protects against mitochondrial toxins, suggesting that interactions
between syn and mitochondria influences the pathologic and physiologic functions of syn. However, we do not know if
syn affects normal mitochondrial function or if lowering syn levels impacts bioenergetic function, especially at the nerve
terminal where syn is enriched. To determine if syn is required for normal mitochondrial function in neurons, we
comprehensively evaluated how lowering syn affects mitochondrial function. We found that syn knockout (KO) does not
affect the respiration of cultured hippocampal neurons or cortical and dopaminergic synaptosomes, and that neither loss of
syn nor all three (,  and ) syn isoforms decreased mitochondria-derived ATP levels at the synapse. Similarly, neither
syn KO nor knockdown altered the capacity of synaptic mitochondria to meet the energy requirements of synaptic vesicle
cycling or influenced the localization of mitochondria to dopamine (DA) synapses in vivo. Finally, syn KO did not affect
overall energy metabolism in mice assessed with a Comprehensive Lab Animal Monitoring System. These studies suggest
either that syn has little or no significant physiological effect on mitochondrial bioenergetic function, or that any such
functions are fully compensated for when lost. These results implicate that syn levels can be reduced in neurons without
impairing (or improving) mitochondrial bioenergetics or distribution.
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Introduction
Increased -synuclein (syn) and mitochondrial dys-
function contribute to the pathogenesis of Parkinson’s
disease (PD). For example, mutation or overexpression of
wild-type syn and mitochondrial or mitochondria-
associated proteins (e.g., PINK1, Parkin, and CHCHD2)
cause monogenic forms of PD (Polymeropoulos et al.
1997; Kruger et al. 1998; Singleton et al. 2003; Valente
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Significance Statement
Parkinson’s disease (PD) is characterized by mitochondrial dysfunction and the accumulation of -synuclein
(syn), and lowering syn levels is a leading therapeutic strategy for PD that is already under clinical investiga-
tion. However, because syn and mitochondria have intersecting functions, we must understand the impact of
lowering syn on mitochondrial function. We analyzed the effects of lowering syn on mitochondrial bioener-
getics, particularly at the nerve terminal where syn concentrates. We found that loss of syn does not impact
the intrinsic bioenergetic function of mitochondria, suggesting that syn does not normally influence respiration,
and that syn levels can likely be lowered without affecting mitochondrial function in PD.
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et al. 2004; Zarranz et al. 2004; Clark et al. 2006; Park
et al. 2006; Funayama et al. 2015). In sporadic PD, syn
accumulates in Lewy bodies and dystrophic neurites
(Spillantini et al. 1998), and mitochondria exhibit promi-
nent changes, including decreased complex I activity in
the substantia nigra (SN) (Schapira et al. 1990) and in-
creased accumulation of mutations in the mitochondrial
DNA of surviving SN dopamine (DA) neurons (Bender
et al. 2006). In addition, changes occur in genes that
regulate mitochondrial functions, including reduced ex-
pression of peroxisome proliferator-activated receptor-
coactivator (PGC)-1 and PGC1-regulated genes in SN
dopamine (DA) neurons (Zheng et al. 2010).
Syn and mitochondria also directly affect each other.
In mice and humans, a fraction of syn associates with
mitochondria in DA neurons (Martin et al. 2006; Li et al.
2007; Devi et al. 2008). Additionally, supra-physiologic
levels of syn disrupt mitochondrial morphology in vitro
and in vivo (Kamp et al. 2010; Nakamura et al. 2011; Butler
et al. 2012), promote excessive mitophagy (Choubey et al.
2011; Sampaio-Marques et al. 2012), disrupt mitochon-
drial protein import (Di Maio et al. 2016) and influence
mitochondrial Ca2 homeostasis and apposition between
the endoplasmic reticulum and mitochondria (Cali et al.
2012; Guardia-Laguarta et al. 2014). Increased syn also
inhibits mitochondrial complex I in cell lines and mouse
brains (Devi et al. 2008; Liu et al. 2009; Chinta et al. 2010;
Loeb et al. 2010), and it correlates with decreased com-
plex I activity in mitochondrial fractions from the SN of PD
patients (Devi et al. 2008).
The effects of increased syn on mitochondria may
result from a toxic gain-of-function, such as the accumu-
lation of oligomeric syn species that interact preferen-
tially with mitochondria (van Rooijen et al. 2009;
Nakamura et al. 2011; Nakamura, 2013; Luth et al. 2014).
Moreover, even basal levels of syn may predispose mi-
tochondria to dysfunction. In syn knockout (KO) mice,
SN DA neurons resist toxicity from mitochondrial toxins,
including 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) (Dauer et al. 2002; Klivenyi et al. 2006), and re-
ducing endogenous syn protects against toxicity from
the complex I inhibitor rotenone (Zharikov et al. 2015) and
may improve mitochondrial protein import (Di Maio et al.
2016). However, excessively lowering syn could also
adversely affect mitochondria. While increased syn
causes mitochondrial fragmentation, decreased syn can
produce excessive mitochondrial tubulation (Kamp et al.
2010; Norris et al. 2015). Additionally, syn KO mice have
decreased levels of the mitochondrial lipid cardiolipin (El-
lis et al. 2005) and lowering syn impairs complex I/III
activity, perhaps by directly interacting with complex I
(Ellis et al. 2005; Devi et al. 2008). In addition, syn TKO
mitochondria have decreased mitochondrial membrane
potential but increased oxygen consumption, and lower
activity of ATP synthase (Ludtmann et al. 2016).
Both syn and mitochondria are major targets for PD
therapy. Lowering syn is under study in clinical trials
(Dehay et al. 2015), but whether this approach is safe
remains unknown. Interestingly, although single-syn KO
(, , or ) and double-syn KO mice ( and ) have normal
lifespans (Chandra et al. 2004), triple-syn KO mice (, ,
and ) die early (Greten-Harrison et al. 2010). These re-
sults suggest that syn mediates essential functions, but
other syn isoforms can compensate for its loss, at least
over the lifespan of a mouse. In addition, the capacity to
compensate for syn loss may decrease once neuronal
maturation is complete. Indeed, some studies found that
lowering syn in adult rodents (Benskey et al. 2016b) or
non-human primates (Collier et al. 2016) using shRNA is
toxic to nigral DA neurons, while other studies have not
(McCormack et al. 2010; Zharikov et al. 2015), with the
discrepancies likely due to varying degrees of syn
knockdown. Therefore, we must better understand the
consequences of lowering syn, particularly on mitochon-
drial function in axons where syn concentrates and en-
ergy failure can selectively occur (Shields et al. 2015).
In this study, we aimed to determine if syn is required
for normal mitochondrial bioenergetics, and if syn levels
can be safely lowered without affecting mitochondrial
bioenergetics. We comprehensively evaluated how the
loss of syn impacts mitochondrial function, including
respiration in neurons and isolated nerve terminals,
mitochondrial-derived ATP levels specifically at synapses
of intact neurons, localization of mitochondria to DA syn-
apses in vivo, and total bioenergetic function.
Materials and Methods
Molecular Biology
All constructs used for transient transfection were sub-
cloned or cloned into the pCAGGS vector downstream of
the chicken actin promoter (Voglmaier et al. 2006). The
AT1.03YEMK FRET sensor was a kind gift from Dr Hiroyuki
Noji at Osaka University (Imamura et al. 2009a). VGLUT1-
pHluorin-mCherry is derived from the VGLUT1-pHluorin
fusion (Voglmaier et al. 2006) and was a kind gift from Dr
Timothy Ryan (Weil Cornell Medical School), mCherry-
synaptophysin has been described (Voglmaier et al. 2006;
Hua et al. 2011), and mTagBFP was a kind gift from Dr
Vladislav Verkhusha at the Albert Einstein College of Med-
icine (Subach et al. 2008). Mitochondria-targeted GFP
(mitoGFP) and mCherry fused to the N-terminus of rat
synaptophysin (Hua et al. 2011) were subcloned into
pAAV-EF1a-DIO-hChR2(H134R)-EYFP-WPRE (Addgene),
unpublished reagents; DP, AB, JB, KY, RS, AO, FM and KN analyzed data; KN
wrote the paper with assistance from co-authors.
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and recombinant adeno-associated virus (AAV)1 was
made by the Vector Core at the University of North Car-
olina.
Viral constructs for syn silencing were similar to those
used before (Gorbatyuk et al. 2010); the siRNA sequences
[syn: GAAGGACCAGATGGGCAAG, scrambled (SCR):
GTCGACAATTCATATTTGC] were expressed as a shRNA
by incorporating the loop structure TTCAAGAGA. The
shRNA cassette was inserted behind an H1 promoter, and
the viral genome also contained mTagBFP2 under the
control of the hybrid chicken -actin/cytomegalovirus en-
hancer promoter (pCBA) as a transduction marker. The
viral vectors were packaged into AAV5 capsids by trans-
fection of 293 cells with the viral genome and the pXYZ5
helper plasmid. Viral particles were purified using an io-
dixanol gradient followed by column chromatography,
and titers were determined by dot-blot (Benskey et al.
2016a).
Knockout and Transgenic Mice
Syn KO mice on a C57BL/6N background (strain
016123, The Jackson Laboratory) (Baptista et al. 2013)
were used for most experiments. Before these mice were
available, syn KO mice on a mixed C57BL/6 and 129 
1/SvJ background (strain 003692, The Jackson Labora-
tory, backcrossed one generation with C57BL/6N con-
trols) were used for experiments outlined in Fig. 2B.
DATcre (Backman et al. 2006) mice were also obtained
from The Jackson Laboratory. C57BL/6N mice served as
controls for all studies. Mice were group-housed in a
colony maintained with a standard 12-h light/dark cycle
and given food on the cage floor and water ad libitum. All
experiments were performed on age- and sex-matched
mice. Experiments were conducted in accordance with
the Guide for the Care and Use of Laboratory Animals, as
adopted by the National Institutes of Health and with
approval of the Authors’ University Institutional Animal
Care and Use Committee.
Cell Culture
Postnatal hippocampal neurons for live-imaging exper-
iments were prepared from P0 rat (Sprague Dawley) or
mouse pups. Hippocampi were dissected in 37˚C Hanks’
BSS supplemented with glucose (20 mM) and HEPES (10
mM) (HBSS) and plated at a density of 85 cells/mm2.
Neurons are grown in neuronal media consisting of Earle’s
Minimum Essential Medium supplemented with 5% fetal
bovine serum (FBS), 21 mM glucose, 1% Glutamax, 2%
B27 supplement (Gibco 17504-044), and 0.1% serum
extender (Fisher 355006). Cells for imaging were tran-
siently transfected by electroporation (Amaxa) and cul-
tured for 8–14 days before live imaging or analysis (Fig. 2),
or transfected with Ca2-phosphate (Jiang and Chen,
2006) on DIV8 and cultured 14–20 days before imaging
(Fig. 3). Hippocampal neurons for Seahorse experiments
were prepared from E18 embryos (to minimize glial con-
tamination (Yao et al. 2011)), plated at a density of 5 104
cells per well of a 96-well polystyrene microplate, and
cultured for 10–11 days before analysis.
Synaptosome Isolation
Cortical synaptosomes were isolated from cerebral cor-
tices of 6-month-old mice as described (Gerencser et al.
2009). Briefly, cortices were quickly dissected, rinsed, and
gently homogenized in ice-cold sucrose buffer (320 mM
sucrose, 1 mM EDTA, 0.25 mM dithiothreitol, pH 7.4).
Homogenates were centrifuged at 1000  g for 10 min at
4°C. The supernatant was layered on top of a discontin-
uous Percoll gradient of 3, 10, and 23% Percoll layers in
sucrose medium and centrifuged at 32500  g for 10 min
at 4°C. Synaptosomes accumulated as a band between
the 10% and 23% Percoll layers and were gently aspi-
rated and washed in HBS medium containing 20 mM
HEPES, 10 mM D-glucose, 1.2 mM Na2HPO4, 1 mM
MgCl2, 5 mM NaHCO3, 5 mM KCl, and 140 mM NaCl at
pH. 7.4. The final synaptosomal pellet was resuspended
in HBS medium.
To prepare dopaminergic synaptosomes, mice striata
were quickly dissected and homogenized using ice-cold
sucrose buffer (Choi et al. 2011). Homogenates were then
incubated with antibodies against the dopamine trans-
porter (Alpha Diagnostic International; 25 g/sample) for
60 min at 4°C and washed three times in sucrose buffer at
10 000  g for 2 min. Pellets were then incubated with
150 l of secondary IgG magnetic beads (Miltenyi) for 45
min at 4°C and then poured into a magnetic column
(MACS LS; Miltenyi) to separate the magnetic bead–la-
beled dopaminergic synaptosomes (bound to column,
DA) from the nondopaminergic fraction that flows through
the column.
Western Blot Analysis
Relative levels of syn (1:2000; catalog #610787, BD Biosci-
ences, RRID:AB_398108), tyrosine hydroxylase (1:4000; cata-
log #MAB318, EMD Millipore, RRID:AB_2201528), and
synaptophysin (1:1000; catalog #ab68851, Abcam, RID:
AB_2199023) in dopaminergic and non-dopaminergic synap-
tosomes were determined by western blotting by standard
procedures. Relative levels of synuclein isoforms [syn (1:1000;
catalog #610787, BD Biosciences, RRID:AB_398108); syn
(1:1000; catalog #AB5086, EMD Millipore Chemicals, RRID:
AB_2239676)] in brain lysates were also assessed by western
blotting. Samples of synaptosomes (23 g) or brain lysates (25
g) were denatured by boiling in an equal volume of 2 Laem-
mli Lysis Buffer (Bio-Rad) for 5 min. Proteins were resolved by
SDS-PAGE before transfer to PVDF membranes and detected
with Pierce ECL substrate (ThermoFisher).
Respiration and Glycolysis
The extracellular-acidification rates (ECAR, a surrogate
for glycolysis) and oxygen-consumption rates (OCR, as-
sesses mitochondrial respiration) were measured in cul-
tured hippocampal neurons using a Seahorse XF96
Extracellular Flux Analyzer (Seahorse Bioscience), an in-
strument that can simultaneously assess aerobic and an-
aerobic metabolism in adherent cells cultured in 96-well
plates. Cells were washed and preincubated for 30 min in
Seahorse assay medium (pH 7.4) containing substrates of
interest (30 mM glucose and 10 mM pyruvate). OCR and
ECAR were measured at baseline and again after sequen-
tial addition of the respiratory inhibitors FCCP (1 M),
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rotenone (3 M), and oligomycin (2 M), or with veratri-
dine (50 M) to increase neural activity (Lysko et al. 1994).
To assess any effects of genotype on cell survival, cells in
a subset of wells were also stained with DAPI (4’,6-
diamidino-2-phenylindole) and quantified using Meta-
Morph software (Universal Imaging).
Aerobic respiration was also measured in cortical and
dopaminergic synaptosomes prepared from syn KO and
control mice. Before plating synaptosomes, Seahorse
plates were coated with 0.0033% (v/v) polyethyleneimine
solution and Geltrex suspension. Synaptosomes were
then added to each well (cortical 20 g/well; dopaminer-
gic 40 g/well), and the plates were centrifuged at 3200
g for 50 mins at 4°C to attach the synaptosomes to the
surface. For Seahorse measurements, HBS medium was
replaced with Seahorse buffer containing 3.5 mM KCl,
120 mM NaCl, 1.3 mM CaCl2, 0.4 mM KH2 PO4, 1.2 mM
Na2SO4, 2 mM MgSO4, 10 mM TES, 10 mM Na-pyruvate,
and 4 mg/ml bovine serum albumin.
Neuronal Culture and Live Imaging
Live imaging was performed in Tyrode’s medium (pH
7.4; 127 mM NaCl, 10 mM HEPES-NaOH, 2.5 mM KCl, 2
mM MgCl2, 2 mM CaCl2, and 10 mM pyruvate, with or
without 30 mM glucose) at room temperature (Fig. 2) on a
Nikon Ti-E inverted microscope with an iXon EMCCD
camera (Andor Technology) and a perfusion valve–control
system (VC-8, Warner Instruments) or at 35°C (Fig. 3) on
a Nikon Eclipse TE300 inverted microscope with a Quan-
tEM:512SC EMCCD camera (Photometrics) controlled by
MetaMorph Software. Field stimulation (5–30 Hz) was
performed with an A385 current isolator and a SYS-A310
accupulser–signal generator (World Precision Instru-
ments). Glycolysis was inhibited with 2-deoxyglucose
(2DG, 2.5–5 mM; Sigma-Aldrich) and iodoacetate (1 mM;
Sigma-Aldrich).
VGLUT1-pHluorin fluorescence images were obtained
[490/20 excitation (ex), 535/50 emission (em) (Fig. 2) or
470/40 ex, 525/50 em (Fig 3); Chroma] and regions of
interest were drawn over synaptic boutons, identified
based on co-localization with mCherry-synaptophysin
(Fig. 2) or VGLUT1-pHluorin-mCherry (Fig. 3). The
background-subtracted change in fluorescence at each
time point was then normalized to the fluorescence in
ammonium chloride measured at the end of each run (Fig.
2) (Nemani et al. 2010) or to the peak fluorescence re-
sponse (F) to the initial stimulus train (Fig. 3). For fluo-
rescence resonance energy transfer (FRET) experiments,
sequential images were taken in the CFP [430/24 ex,
470/24 em (Fig. 2) or 436/10 ex, 465/30 em (Fig.3)], YFP
[(500/20 ex, 535/30 em (Fig. 2) or 495/10 ex, 525/30 em
(Fig. 3)], and FRET [(430/24 ex, 535/30 em (Fig. 2) or
436/10 ex, 525/30 em (Fig. 3)] channels with an ET ECFP/
EYFP filter set (Chroma). Synaptic boutons were identified
based on co-localization with mCherry-synaptophysin.
The FRET/donor ratio was calculated for each bouton as
described (Xia and Liu, 2001), where FRET  (IFRET  ICFP
 BTCFP – IYFP  BTYFP)/ICFP, such that IX is the
background-corrected fluorescence intensity measured
in a given channel. BTCFP (donor bleed through) and BTYFP
(direct excitation of the acceptor) were calculated by ex-
pressing CFP and YFP individually and then determining
the ratios of IFRET/ICFP and IFRET/IYFP, respectively.
Stereotaxic Recombinant Adeno-Associated Virus
and Injection
Stereotaxic injections of adeno-associated virus 1 (AAV1)
expressing mitoGFP and mCherry-Synaptophysin were
performed in 3- and 7-month-old Daticre/wt and Daticre/wt
KO mice. Briefly, 0.5 l of AAV1-EF1-DIO-mitoGFP
(cre-dependent mitoGFP, 8  1012 VG/ml) and 0.5 l
of AAV1-EF1-DIO-Cherry-synaptophysin (cre-dependent
Cherry-synaptophysin, 3  1012 VG/ml) were co-injected uni-
laterally into the substantia nigra/VTA (anteroposterior, –3.0 mm
from bregma; mediolateral, 1.1 mm; dorsoventral, 4.3 mm).
Animals were sacrificed 4 weeks after injection. Seven-
month-old Daticre/wt mice were co-injected with AAV1
expressing cre-dependent mitoGFP and/or cre-dependent
mCherrySynaptophysin, as well as 0.5 l of either AAV2/5-
syn-shRNA-mTagBFP2 (1.8 1013 VG/ml) or AAV2/5- SCR-
shRNA-mTagTagBFP (1.1  1013 VG/ml), and sacrificed 6
weeks after injection.
Histology
Mice were anesthetized and perfused with phosphate
buffered saline (PBS) and then 4% paraformaldehyde (PFA).
Brains were sectioned and processed for immunofluores-
cence. The following primary and secondary antibodies
were used: anti–tyrosine hydroxylase (TH) [(mouse, 1:20000;
catalog #MAB318, EMD Millipore, RRID:AB_2201528)
and (rabbit, 1:1000; catalog #AB152, Millipore, RRID:
AB_390204)], rabbit anti-DsRed (1:1000; catalog #632496,
Clontech, RRID:AB_10015246), mouse anti-syn (1:400;
catalog #610787, BD Biosciences, RRID:AB_2201528), and
Alexa Fluor 488, 594, or 647 anti-mouse or -rabbit IgG
(1:300; Invitrogen). Samples were imaged with the examiner
blind to the genotype with a laser-scanning confocal micro-
scope (LSM510-Meta; Carl Zeiss) equipped with 63  (1.4
NA) and 100  (1.3 NA) PlanApo objectives. For a given
experiment, all images were captured using the same exci-
tation and emission settings.
Stereology
Unbiased stereology was used to quantify the number
of TH-positive neurons in the SN as described (Gorbatyuk
et al. 2010). Sections were visualized using 4x magnifica-
tion (Olympus BX53 microscope equipped with a motor-
ized stage (Olympus, Center Valley, PA) and a Qimaging
2000R camera (Qimaging, Surrey, BC, Canada)), and the
SN was outlined. TH cells from every sixth section were
counted using the optical fractionator method with a 60x
oil objective (Stereo Investigator, MBF Bioscience). The
coefficient of error was calculated according to Gunder-
sen and Jensen (Gundersen and Jensen, 1987) and was
0.1 (Gundersen, m  1).
Comprehensive Lab Animal Monitoring
System Measurements
For metabolic measurements, a Comprehensive Lab
Animal Monitoring System (CLAMS, Columbus Instru-
ments) was used to measure the rates of O2 (VO2) and
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CO2 consumption (VCO2), the respiratory-exchange ratio
(RER; [dot]VCO2/VO2), and the activity level of 6-month-old
male mice (Millership et al. 2012). These measurements
were calculated for both the dark and light cycle for 3
consecutive days. The animals were maintained on a
regular chow diet (10% kcal from fat). The body compo-
sition (lean and fat mass) of the control and syn KO mice
was also analyzed using EchoMRI (Yu et al. 2013).
Results
Loss of syn Does Not Affect Mitochondrial
Bioenergetics at the Nerve Terminal
To determine if syn is required for neuronal respiration,
we measured how syn KO affects the oxygen consump-
tion rate (OCR, a surrogate of respiration) of E18 hip-
pocampal neuronal cultures with a Seahorse instrument.
We examined hippocampal neurons because syn biol-
ogy has been extensively characterized in hippocampal
neurons in culture and in vivo (Greten-Harrison et al. 2010;
Nemani et al. 2010; Scott et al. 2010; Volpicelli-Daley et al.
2011), and syn also aggregates in hippocampal neurons
in PD (Hall et al. 2014). In addition, in contrast to dopa-
mine (DA) neurons that constitute only a fraction of the
total neurons in midbrain cultures, hippocampal neuronal
cultures consist primarily of excitatory pyramidal neurons
(Beaudoin et al. 2012), facilitating their analysis in bulk
assays, such as with the Seahorse. Neuronal cultures
were grown in serum-free media to minimize the glial
content so that respiration is responsible for most of the
OCR signal (Pathak et al. 2015). We found that syn KO
cultures had similar basal and maximal (after treatment
with 1 M FCCP) respiration as controls (Fig. 1A, B). In
addition, increasing neuronal activity with veratridine (50
M) augmented OCR similarly in both groups (Fig. 1C),
suggesting that the respiratory function of syn KO neu-
rons upregulates normally when energy requirements are
increased. Nonetheless, there was a small trend for syn
KO to have decreased basal OCR in several runs (Figs.
1A–C), and we cannot exclude the possibility that syn
KO causes a small impairment in respiration that was
below the sensitivity of the assay (see statistical table).
Notably, syn KO neurons also had similar basal rates of
extracellular acidification (ECAR, a surrogate of glycoly-
sis), which increased similarly after treatment with oligo-
mycin (2 M) (Fig. 1D). These results suggest that syn
KO neurons also have normal glycolytic capacity. Notably
syn KO also did not affect the total number of surviving
cells per well, which was assessed in a subset of wells by
DAPI staining (control: 296.9 cells/100 mm2 6.0, syn
KO: 305.7 cells/100 mm2 7.3; mean  SE, 30 wells per
group).
The aforementioned measurements interrogate the
overall respiration of neurons, but they may not be sen-
sitive to changes in specific subcellular compartments,
such as the nerve terminal. Syn concentrates at syn-
apses, which have high-energy requirements (Rangaraju
et al. 2014; Pathak et al. 2015), suggesting that any
effects of syn KO on bioenergetics would be most prom-
inent in this compartment. To understand the effect of
syn KO on respiration specifically in synapses, we ex-
amined the respiration of synaptosomes isolated from the
brains of 6-month-old control and syn KO mice. We did
not observe differences in the basal or maximal respira-
tion in either cortical or dopaminergic synaptosomes (Fig.
1E, F), although there was a small trend for decreased
respiration in the syn KO dopaminergic synaptosomes.
We next examined how syn KO impacted ATP levels
at the synapse, which reflect the balance between ATP
production and consumption. Syn KO and control neu-
rons from postnatal hippocampi were co-transfected with
ATP FRET sensors (Imamura et al. 2009b) and mCherry-
synaptophysin to identify synaptic boutons and then cul-
tured for 10 days before imaging. As expected, basal ATP
levels were normal with glucose and pyruvate treatment in
syn KO neurons (Fig. 2A). To specifically examine the
capacity of syn KO mitochondria to produce ATP, we
forced neurons to rely on mitochondria-derived ATP by
acutely blocking glycolysis (switching to no-glucose me-
dia with glycolytic inhibitors). Under these conditions, the
assay sensitively detects decreases in energy caused by
either acute pharmacologic or chronic, genetic mitochon-
drial deficits. Specifically, each comparison was sensitive
to an 10%–20% decrease in ATP FRET signal with 90%
power and an alpha of 0.05 (statistical table), while the
FRET must decrease by 40% from baseline to pass the
threshold level (corresponding to 0.8 mM ATP) required
for endocytosis (Pathak et al. 2015; Shields et al. 2015).
Furthermore, because bioenergetic deficits may only ap-
pear when energy requirements increase (Pathak et al.
2015; Shields et al. 2015), we tested if syn KO influences
the ability of synapses to maintain ATP levels when their
energy requirements are increased (Attwell and Laughlin,
2001). Even when neural activity was augmented with
electrical field stimulation (10 Hz60 s) (Nemani et al.
2010), ATP levels decreased similarly with or without syn
(Fig. 2B, C).
We also assessed whether loss of syn affected syn-
aptic vesicle cycling (particularly endocytosis), an ATP-
consuming process that is sensitive to decreases in ATP
(Rangaraju et al. 2014; Pathak et al. 2015; Shields et al.
2015). To monitor synaptic vesicle cycling in individual
boutons, we used the VGLUT1-pHluorin reporter, which
targets a pH-sensitive GFP to the lumen of synaptic ves-
icles. The pHluorin does not fluoresce in acidified vesi-
cles, but does when synaptic vesicles fuse and expose
their contents to the alkaline extracellular environment
(Voglmaier et al. 2006; Nemani et al. 2010). Hippocampal
neurons expressing VGLUT1-pHluorin were incubated in
buffer with 10 mM pyruvate, but without glucose to favor
reliance on mitochondria for energy. Even with glycolytic
inhibitors, synaptic vesicle cycling (10 Hz60 s, which
preferentially targets the recycling pool) was normal in
synaptic boutons lacking syn, further supporting that
mitochondrial-derived ATP persists at functionally signif-
icant levels (Fig. 2D). Because developmental compensa-
tion may occur in syn KO neurons, we also examined
how knocking down syn with shRNA impacts ATP levels
in rat neurons. The shRNA reduced syn expression by
	60% based on immunofluorescence (Fig. 2E); however,
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this decrease did not affect synaptic vesicle cycling (Vogl-
maier et al. 2006; Nemani et al. 2010) (Fig. 2F).
Increased syn can have similar albeit less potent det-
rimental effects to syn on mitochondrial functions (Kamp
et al. 2010; Nakamura et al. 2011), and loss of all three (,
 and , syn TKO) isoforms (but not loss of syn alone)
decreases mouse lifespan, raising the possibility that 
and syn compensate to maintain mitochondrial function
when syn is lost. However, sustained electrical stimula-
tion (5 Hz475s) decreased ATP levels similarly in syn
Figure 1. Syn KO does not impact respiration in cultured neurons or synaptosomes. Aerobic respiration rates (oxygen consumption
rate, OCR) were measured using a 96-well Seahorse Extracellular Flux Analyzer. Arrows show addition of the mitochondrial uncoupler
FCCP (1 M for neurons; 3 M for synaptosomes), the ATP synthase inhibitor oligomycin (oligo, 2 M), or the mitochondrial complex
I inhibitor rotenone (3 M for neurons and synaptosomes). A, Syn KO had no effect on the basal or maximal (after FCCP) respiration
of hippocampal neurons in medium containing 10 mM pyruvate and 30 mM glucose (compilation of two experiments, n  13 wells
per group). B, Oligomycin and rotenone similarly decrease OCR in syn KO and control groups (compilation of two experiments,
n  10 wells per group). C, Increasing neuronal activity with veratridine similarly increased OCR (compilation of two experiments, n
 6 wells per group), while oligomycin similarly increased ECAR (D; extracellular acidification rate, a surrogate of glycolysis;
compilation of two experiments, n  9 wells per group). E, F, cortical synaptosomes (E) and dopamine (DA) synaptosomes (F, right)
isolated from the striatum also had similar basal and maximal rates of respiration (n  15 wells per group from two experiments for
cortical synaptosomes; n  7–8 wells per group from two experiments for DA synaptosomes). As expected, western blotting (F, left)
shows that both control and syn KO DA synaptosomes are enriched in tyrosine hydroxylase (TH). All graphs show mean 
 SEM. NS
 not significant by two-way ANOVA and Sidak’s posthoc test.
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Table 1. Statistics
Row Figure
Data
Distribution Test
Power for
10%
change
Power for
25%
change
Power for
50%
change
Value
detected
with  0.1,
 0.05
a 1A, Seahorse-neuron-baseline Normal Two-way ANOVA, Sidak’s
post hoc test
0.54 1 1 84.2
b 1A, Seahorse-neuron-FCCP Normal Two-way ANOVA, Sidak’s
post hoc test
0.69 1 1 171
c 1A, Seahorse-neuron-rotenone Normal Two-way ANOVA, Sidak’s
post hoc test
0.33 0.97 1 28.6
d 1B, Seahorse-neuron-baseline Normal Two-way ANOVA, Sidak’s
post hoc test
0.15 0.62 1 64.5
e 1B, Seahorse neuron-oligomycin Normal Two-way ANOVA, Sidak’s
post hoc test
0.16 0.68 1 26.8
f 1B, Seahorse neuron-rotenone Normal Two-way ANOVA, Sidak’s
post hoc test
0.17 0.71 1 16.8
g 1C, Seahorse neuron pre-
veratridine
Normal Two-way ANOVA, Sidak’s
post hoc test
0.13 0.53 0.98 60
h 1C, Seahorse neuron post-
veratridine
Normal Two-way ANOVA, Sidak’s
post hoc test
0.13 0.54 0.98 83
i 1D, Seahorse neuron pre-
oligomycin
Normal Two-way ANOVA, Sidak’s
post hoc test
0.2 0.79 1 70.5
j 1D, Seahorse neuron post-
oligomycin
Normal Two-way ANOVA, Sidak’s
post hoc test
0.28 0.93 1 97.5
k 1E, Seahorse, cortical
synaptosomes-baseline
Normal Two-way ANOVA, Sidak’s
post hoc test
0.31 0.95 1 77.5
l 1E, Seahorse, cortical
synaptosomes-FCCP
Normal Two-way ANOVA, Sidak’s
post hoc test
0.16 0.68 1 235
m 1E, cortical synaptosomes-
rotenone
Normal Two-way ANOVA, Sidak’s
post hoc test
0.08 0.3 0.82 15
n 1F, DA synaptosomes-baseline Normal Two-way ANOVA, Sidak’s
post hoc test
0.14 0.6 0.99 63.5
o 1F, DA synaptosomes-FCCP Normal Two-way ANOVA, Sidak’s
post hoc test
0.1 0.39 0.92 120
p 1F, DA synaptosomes-rotenone Normal Two-way ANOVA, Sidak’s
post hoc test
0.05 0.13 0.37 0
q 2A, baseline ATP sensor Normal Unpaired Student’s t-test
(two-tailed)
0.23 0.87 1 2
r 2B, poststim1-imagea Normal Two-way ANOVA, Sidak’s
post hoc test
0.97 1 1 77.2
s 2B, poststim1-Imageb Normal Two-way ANOVA, Sidak’s
post hoc test
0.56 1 1 74.8
t 2B, poststim2-imagea Normal Two-way ANOVA, Sidak’s
post hoc test
0.41 0.99 1 66
u 2B, poststim2-imageb Normal Two-way ANOVA, Sidak’s
post hoc test
0.75 1 1 70.5
v 2C, poststim1-imagea Normal Two-way ANOVA, Sidak’s
post hoc test
0.89 1 1 74.6
w 2C, poststim1-Imageb Normal Two-way ANOVA, Sidak’s
post hoc test
0.99 1 1 85.1
x 2C, poststim2-imagea Normal Two-way ANOVA, Sidak’s
post hoc test
0.82 1 1 65.9
y 2C, poststim2-imageb Normal Two-way ANOVA, Sidak’s
post hoc test
0.93 1 1 63.8
z 2D, synKO pHluorin-stim1 Normal Two-way ANOVA, Sidak’s
post hoc test
0.51 1 1 0.794
aa 2D, synKO pHluorin-stim2 Normal Two-way ANOVA, Sidak’s
post hoc test
0.3 0.95 1 0.718
ab 2E, syn knockdown level Normal Unpaired Student’s t-test
(two-tailed)
0.28 0.93 1 76.5
ac 2F, syn shRNA pHluorin-stim 1 Normal Two-way ANOVA, Sidak’s
post hoc test
0.07 0.23 0.7 0.38
ad 2F, syn shRNA pHluorin-stim 2 Normal Two-way ANOVA, Sidak’s
post hoc test
0.85 1 1 0.932
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TKO and control synaptic boutons, suggesting that con-
current loss of isoforms does not affect mitochondria-
derived ATP levels at the nerve terminal (Fig. 3A). As ATP
levels depend on the balance between energy production
(aerobic respiration and glycolysis) and consumption, we
also assessed if syn TKO might impact the rate of ATP
consumption. However, when energy production was
blocked (the respiratory chain was blocked with rotenone
(2 M), and external glucose was removed to limit glyco-
lysis), and energy consumption was increased with repet-
itive electrical stimulation (30 Hz5s every 120s), the
stimulus-dependent endo- and exocytic response of syn
TKO and control boutons failed at the same rate (Fig.
3B-D), indicating that ATP levels fell below the threshold
level needed to support synaptic vesicle cycling at the
same rate (Pathak et al. 2015; Shields et al. 2015). Since
the ATP level reflects a balance between ATP production
and consumption, these results suggest that the net bal-
ance of ATP consumption and any residual ATP produc-
tion by glycolysis is also similar in syn TKO and control
synaptic boutons.
Lowering syn Does Not Impact Mitochondrial
Distribution in Axons
Even when the intrinsic function of individual mitochon-
dria is normal, changes in the distribution of mitochondria
could create regions within neurons (especially axons)
without sufficient mitochondria to meet energy require-
ments, leading to energy failure in that region. Syn pri-
marily locates to presynaptic terminals (Jakes et al. 1994;
Iwai et al. 1995), and mutant A53T syn decreases the
movement and density of mitochondria in axons
(Choubey et al. 2011; Li et al. 2013). To determine if
endogenous syn influences the localization of axonal
mitochondria to synapses, we used cre-dependent AAV-
based viral reporters to visualize mitochondria
[mitochondrial-targeted GFP (mitoGFP)] specifically in in-
dividual DA neurons and their synapses (mCherry-
Row Figure
Data
Distribution Test
Power for
10%
change
Power for
25%
change
Power for
50%
change
Value
detected
with  0.1,
 0.05
ae 3A, syn TKO ATP sensor Normal Two-way ANOVA, Sidak’s
post hoc test
0.21 0.82 1 0.645
af 3D, syn TKO pHluorin Normal Unpaired Student’s t-test
(two-tailed)
0.32 0.96 1 2.93
ag 4B, syn KO mito boutons
4 months
Normal Unpaired Student’s t-test
(two-tailed)
0.42 0.99 1 47.5
ah 4B, syn KO mito boutons
8 months
Normal Unpaired Student’s t-test
(two-tailed)
1 1 1 54.1
ai 4C, Western syn Normal One-way ANOVA,
Dunnett’s post hoc test
0.6 1 1 85.2
aj 4C, Western syn Normal One-way ANOVA,
Dunnett’s post hoc test
0.05 0.13 0.37 1
ak 4E, shRNA syn level in vivo Normal Unpaired Student’s t-test
(two-tailed)
1 1 1 75.4
al 4F, stereology Normal Unpaired Student’s t-test
(two-tailed)
0.47 1 1 0.715
am 4G, shRNA mito boutons Normal Unpaired Student’s t-test
(two-tailed)
0.72 1 1 50.5
an 5A, lean body mass Normal Two-way ANOVA, Sidak’s
post hoc test
1 1 1 20.1
ao 5A, fat body mass Normal Two-way ANOVA, Sidak’s
post hoc test
0.39 0.99 1 2.58
ap 5B, food intake Normal Unpaired Student’s t-test
(two-tailed)
0.42 0.99 1 4
aq 5C, activity light cycle Normal Two-way ANOVA, Sidak’s
post hoc test
0.06 0.18 0.54 53
ar 5C, activity dark cycle Normal Two-way ANOVA, Sidak’s
post hoc test
0.09 0.36 0.9 360
as 5D, VO2 light cycle Normal Two-way ANOVA, Sidak’s
post hoc test
1 1 1 2.99
at 5D, VO2 dark cycle Normal Two-way ANOVA, Sidak’s
post hoc test
1 1 1 3.64
au 5E, VCO2 light cycle Normal Two-way ANOVA, Sidak’s
post hoc test
0.1 0.4 0.93 1.68
av 5E, VCO2 dark cycle Normal Two-way ANOVA, Sidak’s
post hoc test
0.1 0.4 0.93 1.68
aw 5F, RER light cycle Normal Two-way ANOVA, Sidak’s
post hoc test
1 1 1 0.829
ax 5F, RER dark cycle Normal Two-way ANOVA, Sidak’s
post hoc test
1 1 1 0.853
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synaptophysin) (Berthet et al. 2014) in DATcre control and
syn KO-DATcre mice that express Cre recombinase
selectively in Slc6a3 (dopamine transporter, DAT)-
expressing DA neurons (Backman et al. 2006). Syn KO
did not affect the proportion of DA boutons containing
mitochondria (	60%) in the caudate putamen (CPu) (Fig.
4A, B).
Notably, syn KO mice may have developmental
changes that compensate for the loss of syn (Kuhn et al.
2007). Although we did not detect changes in the level of
syn in total brain lysates (Fig. 4C), other groups found it
upregulated in the midbrain of syn KO mice (Robertson
et al. 2004; Thomas et al. 2011) and that compensation
could occur independent of changes in expression. To
further exclude the possibility of any developmental com-
pensation, we also examined if lowering syn with shRNA
in adult mice (Gorbatyuk et al. 2010; Kanaan and Man-
fredsson, 2012) would impact the axonal localization of
mitochondria. Using AAV expressing an shRNA against
syn, we lowered syn levels in DA neurons by 	60%
(Figs 4D-E, 4E-1) (as measured by immunofluorescence),
a level of decrease that may not be quite sufficient to
produce neuronal loss in rats (Gorbatyuk et al. 2010), and
mice may also be more resistant (Benskey et al. 2016b).
Consistent with this, there was no significant loss of DA
neurons in the syn shRNA group (Fig. 4F), although there
was a trend for decreased TH counts. This level of syn
decrease also did not affect the proportion of boutons
containing mitochondria (Fig. 4G). Therefore, syn levels
can be significantly lowered in DA neurons without im-
pacting the synaptic targeting of mitochondria. We cannot
exclude the possibility that further lowering of syn by
shRNA such that the DA neurons die would have dis-
rupted mitochondria, and it would be difficult to attribute
such a change specifically to syn lowering as mitochon-
dria are typically disrupted during neuronal death, regard-
less of the cause. Nonetheless, when considered with the
lack of effect in syn KO mice, our data suggest that
either syn does not normally impact mitochondrial dis-
tribution in DA axons or that other factors compensate for
syn loss (Nakamura et al. 2011).
Syn is expressed throughout the brain, including in
regions that influence respiration and metabolism. Syn is
also present at high levels in certain peripheral tissues
including in red blood cells, liver and spleen (Kuo and
Nussbaum, 2015), and phosphorylated syn accumulates
Figure 2. Loss of syn does not affect mitochondrial-derived ATP levels at the nerve terminal. A–C, ATP levels of hippocampal
neurons were assessed using an ATP YEMK FRET sensor, and synaptic boutons were identified with mCherry-synaptophysin. Basal
ATP levels in Tyrodes buffer containing glucose and pyruvate were identical in neurons isolated from control and syn KO mice (A;
n  14–15 coverslips, not significant (NS) by unpaired two-tailed t test). Electrical field stimulation (10 Hz60 s, blue lines) in pyruvate
buffer without (B) and with (C) 2-deoxyglucose (2DG, 5 mM) and iodoacetate (IAA, 1 mM) to completely block glycolysis reduced ATP
levels similarly in neurons in control and syn KO mice (compilation of two experiments, n  6–7 coverslips/group with 15–20
boutons/coverslip). NS for ATP level of syn KO versus control groups at corresponding time points. Note that overall ATP levels
(control and syn KO) decreased after the first electrical stimulation (B and C, p 0.01 for ATP at 10 min versus 9 min pre-stimulation
time points), while the acute drop in ATP levels after the second stimulations did not reach significance. D–F, Synaptic transmission
at individual boutons was assessed using a pH-sensitive GFP targeted to synaptic vesicles (VGLUT1-pHluorin), again in pyruvate
buffer, as well as 2DG and IAA to force reliance on glycolysis. Neither syn KO (D) or shRNA against syn (E, F) affected synaptic
vesicle cycling after repeated stimulation (10 Hz60 s, blue lines). Bar graph confirms that shRNA decreased syn levels by
immunofluorescence (E) (compilation of three experiments, n  10–12 coverslips/group with 10–15 cells/coverslip). NS for extent of
endocytosis [(amplitude endocytosis)/(amplitude exocytosis)] versus respective control by two-way ANOVA and Sidak’s posthoc test.
All graphs show mean 
 SEM.
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in peripheral tissues in PD (Beach et al. 2010). However,
there is very little information on if syn expression in
these areas impacts metabolic functions. Because syn-
lowering therapies will likely lower syn levels throughout
the brain and in peripheral tissues, we also examined if
interactions between syn and mitochondria affect en-
ergy metabolism on a whole-body level using metabolic-
cage analyses and CLAMS (Columbus Instruments). At 6
months of age, syn KO mice had total and lean body
masses similar to controls, as assessed by EchoMRI (Fig.
5A). Food consumption (Fig. 5B) and total locomotor
activity (Fig. 5C) were also unchanged, although the as-
sessment of activity lacked sensitivity due to high variabil-
ity, and there was a trend toward less movement in the
dark cycle in the syn KO group. However, importantly,
syn KO did not affect oxygen consumption (VO2), carbon
dioxide production (VCO2), or the respiratory-exchange
ratio (RER; [dot]VCO2/VO2) in either the light or dark cycle
(Fig 5D–F). Taken together, these data strongly suggest
that loss of syn does not impact total energy consump-
tion in mice.
Discussion
Syn likely plays a central role in the pathogenesis of
sporadic PD. Mitochondria are also compromised in PD,
so therapeutic lowering of syn will be done in the context
of damaged mitochondria. In addition, increased syn
disrupts a range of mitochondrial functions, suggesting
that decreasing syn also influences mitochondrial func-
tion. However, here, we show that loss of syn does not
significantly impact the intrinsic bioenergetic function of
mitochondria (i.e., respiration and ATP levels) in rodent
neurons, even regionally at the synapse where syn con-
centrates. Loss of syn also fails to influence the local-
Figure 3. Loss of all three (,  and ) syn isoforms does not affect mitochondria-derived ATP or activity-dependent ATP consumption
at the nerve terminal. (A) ATP levels of syn TKO and control hippocampal neurons expressing the ATP FRET sensor were assessed
in normal Tyrode’s buffer with either glucose (30 mM) or 2DG (30 mM) without glucose. Neurons were imaged with or without electrical
field stimulation (5 Hz) as indicated. Stimulation with 5 Hz for 475 s in 2DG decreased the FRET signal similarly in wt and TKO neurons
(2-way ANOVA, interaction p  0.99) Data are plotted as mean 
 SEM by coverslip. n  4 (wt) and 5 (TKO) coverslips for 5 Hz
stimulus/2DG, and 2 coverslips (wt and TKO) for non-stimulated glucose and 2DG controls (50 boutons per coverslip) (B–D) Neurons
expressing VGLUT1-pHluorin-mCherry were perfused in Tyrodes containing 30 mM glucose (without pyruvate) and stimulated at 30
Hz for 5 s. After continued perfusion for 5 min in either glucose or in 2 M rotenone without glucose, neurons were stimulated with
repeated 5 s 30 Hz bursts every 120 s (blue boxes). (B) Sample fluorescence traces from single representative VGLUT1-pHluorin
boutons in wild-type (lower) and syn TKO (upper) neurons in rotenone, (C) Average fluorescence responses. Data were normalized to
the second stimulus response, and points represent mean values by coverslip 
 SEM. n  7 (wt) and 8 (TKO) coverslips (18-50
boutons per coverslip) for pyruvate/rotenone experiments, from two independent experiments. (D) Fluorescence traces from
individual boutons (as in (A)) were scored with regard to synaptic vesicle cycling response at each stimulus burst. The stimulus burst
at which the response failed was recorded, and data were plotted as survival curves. Boutons were scored as failed if stim F was
10% of the F from first stim, or if F 120s after stimulus was 33% of the peak Fstim-F0 value (ie endocytic failure). Wt and syn TKO
boutons in rotenone without glucose progressively failed to respond at a similar rate (p 0.21 by Gehan-Breslow-Wilcoxon test). n 325
(wt) and 340 (TKO) boutons for rotenone/no glucose, 98 (wt) and 93 (TKO) boutons for glucose-containing Tyrode’s. The average lifespan
of boutons by coverslip in rotenone/no glucose was also similar (wt  3.75 
 0.253 and syn TKO  3.61 
 0.137).
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Figure 4. Loss of syn does not affect the distribution of mitochondria in axons of nigrostriatal DA neurons in vivo. A–B,
Adeno-associated viruses (AAVs) expressing mitochondria-targeted GFP (mitoGFP; green, to visualize mitochondria) and mCherry-
Synaptophysin (red, to visualize synaptic boutons) in DIO constructs (Sohal et al. 2009) that express only in Cre-expressing neurons
were coinjected into the substantia nigra pars compacta (SNc) of 3- and 7-month-old DATcre control and syn KO-DATcre mice. Mice
were sacrificed one month later at 4 and 8 months of age, respectively. Roughly 60% of control and syn KO synaptic boutons show
mitochondria in the caudate putamen (CPu) (n  3–4 mice per group, where each value is the mean of 18–21 fields; NS  not
significant by two-way ANOVA and Sidak’s posthoc test). C, Western blot shows that syn KO mice have similar levels of syn as
controls (n  3 mice per group; p  0.05, p  0.001 by one-way ANOVA and Dunnet’s posthoc test). D–G, AAVs expressing
expressing mitoGFP and mCherry-Synaptophysin in DIO constructs were co-injected with shRNA scramble TagBFP or shRNA syn
TagBFP into the SNc of 7-month-old Daticre/wt mice, and brains were harvested 6 weeks later. D–E, shRNA against syn decreased
syn immunofluorescence 	60% versus shRNA scramble in DA neurons (n  3–4 mice, 57–86 cells per mouse (syn immunoflu-
orescence level of individual cells for each mouse is shown in Fig. 4E-1); p  0.001 by unpaired two-tailed t test), identified by
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ization of mitochondria in DA axons or disrupt normal
energy consumption in the whole body. Thus, our findings
suggest that either syn has no significant physiologic
impact on mitochondrial bioenergetic function, or that any
such functions are fully compensated for when lost or
emerge only in the presence of specific stressors.
Increased syn expression selectively inhibits complex
I function (Devi et al. 2008; Liu et al. 2009; Chinta et al.
2010; Loeb et al. 2010) or the flux between complex I and
III (Ellis et al. 2005; Devi et al. 2008). However, we do not
yet understand the precise mechanisms of these effects
or if the decrease in complex I function impacts energy
production. Insufficient energy could also result from
changes in the mass or distribution of mitochondria, even
if the mitochondria have normal function. Indeed, in-
creased mutant A53T syn augments Parkin-dependent
mitophagy in cortical neurons (Choubey et al. 2011) and
the number of mitochondria in autophagosomes in mid-
brain DA neurons (Chinta et al. 2010). However, we found
that decreased syn did not affect the bioenergetic func-
tion of mitochondria, including regionally at the synapse,
or the mass or distribution of mitochondria in nigrostriatal
DA neurons in vivo.
The lack of effect of synKO on bioenergetic function
has three potential explanations. The first is that syn KO
does actually impair bioenergetic function but our studies
failed to detect this due to insufficient sensitivity. Indeed,
many of our assays lacked the sensitivity to reliably detect
changes less than 10% - 15%, and hence, subtle
changes would not have been detected. However, all of
the approaches used to assess bioenergetic function
have been validated for their sensitivity to detect the
effects of acute pharmacologic and chronic genetic inhib-
itors of respiration, and the uniform lack of significant
changes across multiple complementary approaches pro-
vides strong evidence that syn KO does not significantly
impact bioenergetic function in the paradigms studied.
Insufficient sensitivity could also have resulted if we as-
sayed the wrong type of cell or the wrong subcellular
compartment. In particular, our study focuses on neurons
because syn primarily localizes to neurons normally and
accumulates in neurons in PD. Moreover, within neurons,
we focused on synapses where most syn KO localizes.
To specifically assay nigrostriatal DA neurons we examine
DA synaptosomes. However, recognizing the potential for
artifact from the antibody bead-based isolation of DA
synaptosomes, we also examined cortical synaposomes
that were isolated without use of antibodies. Since syn-
aptosomes likely have distinct bioenergetic properties
from intact neurons, and even the standard isolation of
continued
tyrosine hydroxylase (TH), but had no effect on either the number of TH neurons as measured by stereology (F; n 6-8 mice per group;
NS  not significant (p  0.16) by unpaired two-tailed t test) or on the localization of mitochondria to synaptic boutons (G; n  3–4 mice
per group, where each value is the mean of 6–10 fields; NS not significant by unpaired two-tailed t test). All graphs show mean
 SEM.
Figure 5. syn KO does not impact total body metabolism in mice. A, Body composition was measured using EchoMRI. Control and
syn KO had identical lean and fat body mass composition at 6 months of age. B–F, Body metabolism was assessed using a
Comprehensive Lab Animal Monitoring System (CLAMS; Columbus Instruments). syn KO and control mice had similar daily food
intake (B) and locomotor activity (C). They also had similar VO2 (D), VCO2 (E), and respiratory exchange ratio (RER, ratio of VCO2
produced and VO2 used) (F) during both the light and dark cycles. n  6 mice per group; NS  not significant by two-way ANOVA
and Sidak’s posthoc test. All graphs show mean 
 SEM.
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cortical synaptosomes may introduce artifacts, we as-
sayed mitochondria-derived ATP levels in individual syn-
aptic boutons of live neurons in complementary assays.
Insufficient sensitivity for an effect of decreasing syn
on bioenergetics could also have resulted if decreasing
syn affects only certain neuron types that we failed to
assay. For instance, although we assayed DA neurons
when possible, many of our assays focused on hip-
pocampal neurons. However, we hypothesize lowering
syn will have similar effects across most neuron types.
Indeed, syn is present in neurons throughout the brain
and, undoubtedly, has normal functions outside of nigro-
striatal DA neurons. (Bendor et al. 2013; Benskey et al.
2016b) Thus, we must understand the impact of lowering
syn on nonDA neurons, in addition to DA neurons, since
any syn lowering therapy will likely be delivered to the
entire brain. Moreover, the fact that human nigrostriatal
DA neurons are susceptible to increased syn in familial
forms of PD does not mean they will also be more sus-
ceptible to syn loss. In fact, it could mean just the
opposite, and the underlying mechanisms of toxicity of
increasing versus decreasing syn could also be very
different. For instance, increased syn in some forms of
PD may cause toxicity through a toxic gain of function of
syn, but loss of syn could produce toxicity through loss
of its normal function. Moreover, in PD, syn accumulates
in many nonDA neurons, including hippocampal neurons
(e.g., see Hall et al. Brain, 2014), presumably contributing
to the many non-motor features of the disease. As such,
hippocampal neurons are an important and appropriate
system to study normal syn biology, and the wealth of
preexisting studies in this neuron type facilitates interpre-
tation of our results. However, the possibility remains that
syn-lowering compromises bioenergetics only in certain
other neuron types.
A second possibility for a lack of effect of decreasing
syn on bioenergetic function is that syn may normally
interact with mitochondria and influence respiration, but
the effects of syn loss may be compensated for by other
factors, such as syn, which has similar, albeit less, po-
tent effects on mitochondrial morphology when overex-
pressed (Nakamura et al. 2011; Taschenberger et al.
2013). Indeed, the three syn isoforms can compensate for
each other, because syn, syn, and syn single–KO
mice and syn/syn double–KO mice have normal lifes-
pans (Chandra et al. 2004), but triple syn–KO mice die
early (Greten-Harrison et al. 2010). As evidence against
this possibility, however, we found no effect of synTKO on
mitochondria-derived ATP levels at the nerve terminal or
on the rate of ATP consumption. In apparent contradic-
tion, Ludtmann et al. (Ludtmann et al. 2016) recently
reported that synTKO neurons have impaired bioenergetic
function, suggesting that other syn isoforms compensate
for certain syn-effects on mitochondria. The reasons for
this discrepancy are unclear, but could reflect differences
between subcellular compartments. Specifically, our
studies on synTKO neurons focused on changes at the
nerve terminal where syn and syn accumulate. They
also observed ATP changes using a mitochondria-
targeted ATP sensor, while we examined cytosolic ATP
levels, raising the possibility that synuclein isoforms might
specifically alter ATP levels in the mitochondria. However,
other methodological differences including the use of per-
meabilized versus intact neurons and the use of Mg2
homeostasis (versus our use of synaptic vesicle cycling)
to assay for ATP consumption may also underlie some of
the differences, and will require additional experimenta-
tion to resolve.
A third possibility is that syn normally has minimal
interactions with mitochondria and little effect on bioen-
ergetic function. Although increased syn disrupts mito-
chondrial morphology and function, these effects may
reflect direct toxicity from the interaction of syn oligom-
ers with mitochondria (van Rooijen et al. 2009; Nakamura
et al. 2011; Nakamura, 2013; Luth et al. 2014), and they
may not occur under normal conditions. Also, while en-
dogenous syn can influence mitochondrial morphology
(Kamp et al. 2010; Norris et al. 2015), and disrupt mito-
chondrial protein import (Di Maio et al. 2016), these
changes may not be sufficiently robust to compromise
respiration under basal conditions, although may be more
prominent under pathologic conditions as in PD. Further-
more, although syn KO mice resist MPTP and other
mitochondrial toxins (Dauer et al. 2002; Klivenyi et al.
2006), and decreasing endogenous syn levels protects
against rotenone (Zharikov et al. 2015), the mechanism of
these effects may be independent of bioenergetic func-
tion and the other parameters studied here.
Importantly, our study does not exclude the notion that
lowering syn may impact other mitochondrial functions,
such as mitochondrial Ca2 import and buffering (Cali
et al. 2012; Guardia-Laguarta et al. 2014), reactive oxygen
species production, and lipid metabolism (Ellis et al. 2005;
Cole et al. 2008; Nakamura et al. 2008; Nunnari and
Suomalainen, 2012). Nonetheless, significant changes in
any of these parameters would likely affect bioenergetic
function and mitochondrial morphology, suggesting that
any such changes would likely be subtle.
Our findings show that syn can be safely lowered in
mice without affecting mitochondrial bioenergetics. We
believe that these studies suggest that therapeutically
lowering syn is unlikely to further disrupt mitochondrial
bioenergetic function in PD. These results will need to be
established in humans, especially if intended for therapies
for PD patients, which will require many years. Moreover,
lowering syn could also produce toxicity through non-
mitochondrial functions, such as disrupting synaptic ves-
icle release. Considering the rapid development of syn-
lowering therapies, we can expect to gain new insights
into the safety and biological impact of syn-lowering
therapies over the coming decade.
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